Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Operating Expenses (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Operating Expenses for 16 consecutive years, with $90.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 14.93% year-over-year to $90.8 million, compared with a TTM value of $331.2 million through Dec 2025, up 11.67%, and an annual FY2025 reading of $331.2 million, up 11.67% over the prior year.
  • Operating Expenses was $90.8 million for Q4 2025 at Catalyst Pharmaceuticals, up from $82.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $139.9 million in Q3 2023 and bottomed at $20.4 million in Q1 2021.
  • Average Operating Expenses over 5 years is $57.0 million, with a median of $60.7 million recorded in 2023.
  • The sharpest move saw Operating Expenses soared 335.18% in 2023, then plummeted 44.39% in 2024.
  • Year by year, Operating Expenses stood at $25.6 million in 2021, then grew by 17.17% to $30.0 million in 2022, then skyrocketed by 129.92% to $68.9 million in 2023, then increased by 14.67% to $79.0 million in 2024, then rose by 14.93% to $90.8 million in 2025.
  • Business Quant data shows Operating Expenses for CPRX at $90.8 million in Q4 2025, $82.1 million in Q3 2025, and $80.3 million in Q2 2025.